How profitable is Bruker Corporation (BRKR)?

In FY 2025 (10-K), BRKR converted $3.4B of revenue into a 45.9% gross margin, 2% operating margin, and $43.3M in free cash flow (1.3% FCF margin).

Stock Ratings / Health Care / BRKR / financials

TXG (59) BIO (62) AVTR (56) RVTY (65) ⌘ Pro Terminal →

Bruker Corporation (BRKR) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$55.69 -2.42% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $55.34

Bruker Corporation (BRKR) carries a Roarable Rating of D+ (Sell) with 54/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D+ • SELL / AVOID Cap $8.70B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on BRKR Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is BRKR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Bruker Corporation (NASDAQ: BRKR) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 54/100 at a spot price of $55.69 (-2.42% 1D, market cap $8.70B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 12/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 11/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, BRKR ranks #209 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does BRKR compare to TXG and BIO in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Laboratory Analytical Instruments), BRKR carries a Roarable D+ (54/100 RQD), trailing P/E of N/A, gross margin of 45.9%, and ROIC of 1.3%. By comparison, TXG (10x Genomics Inc.) holds a C- grade (59/100 RQD, P/E N/A, ROIC -5.7%, cap $9.13B) and BIO (Bio-Rad Laboratories Inc.) posts a C grade (62/100 RQD, P/E 13.5x, ROIC 0.5%, cap $9.95B). Among the 5-stock peer group, BIO leads on earnings multiple (13.5x) while RVTY leads on capital efficiency (3.1% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for BRKR?

▼

Per BRKR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001109354), Bruker Corporation generated $3.44B in revenue (+2.1% YoY), -$8.3M in net income, and $43.3M in free cash flow against $6.24B in total assets and $1.85B in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $55.34 (-0.63%)🧬 Disciplined Float (+0.80% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 1.3% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 54/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.7% avg 90D alpha vs SPY • 51.0% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D+

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D+ · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-1.8% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for BRKR)Realized 20D OHLCV Swing Band: ±9.8%

Deterministic 5-Pillar Attribution (54/100 Composite)

🔍 WHY BRKR SCORES 54/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Cash Engine Quality+12/20 pts (22% of score)

SEC XBRL FY 2025 (10-K): 1.3% FCF Margin ($43.3M FCF) & 45.9% Gross Margin

▲ #2 Bullish Driver: Whale & Options Positioning+12/20 pts (22% of score)

20D Institutional Volume Accumulation (±9.8% realized swing band)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution9/20 pts (-11 pt drag)

Disciplined Float (+0.80% YoY Shares) & executive Form 4 sales trim 11 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$55.60+6.3% Next Q

Q2 (-2Q)

Grade D$59.11+4.9% Next Q

Q3 (-1Q)

Grade C-$62.00-10.2% Next Q

Current

Grade D+$55.69-0.7% Hist 90D α

Trajectory: D (46) → D+ (54)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a BRKR Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While BRKR currently carries a cautious 54/100 (D+) rating due to Insider Conviction & Share Dilution (9/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($59.05) and Max Pain ($58.47) forces dealer call-delta covering toward $70.33.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.80% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $BRKR• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “BRKR Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 54%NO 46%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How BRKR Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$43.3M (1.3% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $2.96B

FY24

Rev $3.37B

FY25

Rev $3.44B

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$3.44B	45.9%	2%	-$8.3M	$43.3M	1.3%
FY 2024	$3.37B	49%	7.5%	$113.8M	$136.0M	5.5%
FY 2023	$2.96B	45.9%	14.7%	$428.5M	$216.7M	11%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring BRKR)

✓Walkthrough of BRKR's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

BRKR // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +53.04%🛡️ HOLDING TREND SUPPORT

2026-11-03O $62.00H $62.00L $55.69C $55.69VOL 1.92M

RES: $67.73SUP: $55.71SMA50: $59.05SMA200: $50.38

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

BRKR Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 BRKR Butterfly Map → + Track BRKR →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

15.7%/yr Implied 5Y Growth

vs. +2.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on BRKR today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for BRKR. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for BRKR today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BRKR)

Health Care Rank #209 of 1015 ⚔️ TXG vs BRKR Full Matrix →

1. Head-to-Head Health Care Peer Comparison (BRKR vs. TXG, BIO, AVTR, RVTY)

Industry: Biotechnology: Laboratory Analytical Instruments (21 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Bruker Corporation (BRKR) ranks #209 by composite RQD confidence (54/100, grade D+) and #123 by equity capitalization ($8.70B). Within this direct 5-issuer industry benchmark cohort, BIO leads on earnings valuation at 13.5x trailing P/E, while RVTY leads on capital efficiency and profitability with 3.1% ROIC and — gross margin. RVTY currently holds the highest overall quantitative score in the immediate peer group at 65/100 (C) compared with BRKR at 54/100 (D+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
BRKR ACTIVE Bruker Corporation	D+	54/100	—	45.9%	1.3%	-2.42%	$8.70B	Benchmark Subject
TXG 10x Genomics Inc.	C-	59/100	—	69.1%	-5.7%	-12.09%	$9.13B	/txg-vs-brkr →
BIO Bio-Rad Laboratories Inc.	C	62/100	13.5x	51.9%	0.5%	-1.62%	$9.95B	/bio-vs-brkr →
AVTR Avantor Inc.	D+	56/100	—	32.7%	-2.1%	-2.74%	$10.88B	/avtr-vs-brkr →
RVTY Revvity Inc.	C	65/100	76.7x	—	3.1%	-3.44%	$17.52B	/rvty-vs-brkr →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001109354 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Bruker Corporation (BRKR) reported GAAP revenue of $3.44B (+2.1% vs. FY2024 revenue of $3.37B , and +15.9% cumulative change since FY2023) , GAAP net income of -$8.3M, operating cash flow of $134.1M, and free cash flow of $43.3M (-68.2% YoY). On the balance sheet, BRKR closed FY2025 with $6.24B in total assets against $1.85B in total debt (Altman Z-Score: 2.81, Piotroski F-Score: 6/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$3.44B	-$8.3M	$134.1M	$43.3M	$6.24B	$1.85B
FY2024 (FY)	2024-12-31	$3.37B	$113.8M	$251.3M	$136.0M	$5.81B	$2.06B
FY2023 (FY)	2023-12-31	$2.96B	$428.5M	$350.1M	$216.7M	$5.20B	$1.22B

3. BRKR Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is BRKR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does BRKR compare to TXG and BIO in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for BRKR?

Where is BRKR trading relative to its 50-day, 200-day, and 52-week technical levels?

BRKR last traded at $55.69 (-2.42% on volume of 1,894,583 shares), positioning the stock -5.69% below its 50-day simple moving average ($59.05) and +10.54% above its 200-day simple moving average ($50.38). Across its 52-week range of $32.37 to $66.98, BRKR sits at the 67.4% percentile with a 14-day RSI of 45.8 (NEUTRAL RANGE) and an implied next-earnings move of ±9.8% ($50.23 to $61.15).

Direct Sub-Reports: BRKR RQD Cockpit BRKR 12M Forecast BRKR Earnings & Move BRKR Dividends & DRIP BRKR Insiders & 13F BRKR Whale Options BRKR Profit Sankey BRKR News & Why

ROARABLE RATING BRIEF • RQD 54/100 (D+) ✓ SEC XBRL & RQD VERIFIED

BRKR — Bruker Corporation: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Bruker Corporation (BRKR) earns a live Roarable RQD composite score of 54/100, corresponding to a D+ letter grade (Roarable Sell) at a spot price of $55.69 (-2.42% 1D, market capitalization $8.70B).

Fundamental Cash Engine (12/20): Anchored by return on invested capital (ROIC) of 1.3%, gross margin of 45.9%, operating margin of 2.0%, and free cash flow yield of 0.46%.
Whale 13F & Options Flow (12/20) + Insider Conviction (9/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (11/20) + Forensic Balance Sheet (10/20): Incorporates a 0.97x equity beta, Altman Z-Score of 2.81, Piotroski F-Score of 6/9, and Debt/Equity of 0.75x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Bruker Corporation (BRKR) is a NASDAQ-listed issuer classified in the Health Care sector and the Biotechnology: Laboratory Analytical Instruments industry. The profile states a market capitalization of $9.4B. Per the market data, gross margin is 45.9%, indicating the product mix carries meaningful pricing power at the gross level.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Bruker Corporation (BRKR) reported $3.44B in annual revenue (up from $3.37B in FY2024, +2.1% YoY) and -$8.3M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($2.96B revenue, $428.5M net income) through FY2025, BRKR scaled operating cash flow to $134.1M and free cash flow to $43.3M, backed by $6.24B in total assets against $1.85B in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (D+ • RQD 54/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of 0.46% and institutional whale pillar of 12/20. With Fundamental Cash Engine at 12/20 and Institutional Whale Flow at 12/20, sustained execution supports upside toward the upper end of the $32.37 – $66.98 52-week range.
🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation and 75.7x EV/EBITDA against 2.0% operating margins and a 0.97x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

No upstream or downstream links, sector correlations, or proprietary signals are recorded; the supply chain is listed as "NONE. Investors should note this gap, as it removes a structural view of how suppliers, customers, or sector peers might transmit shocks to BRKR. The sector and industry classification (Health Care; Biotechnology: Laboratory Analytical Instruments) is the only contextual link available.

Key Question #1: Can BRKR sustain or expand its 2.0% operating margin and 1.3% ROIC against Biotechnology: Laboratory Analytical Instruments peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $3.44B and free cash flow of $43.3M, how will capital allocation balance growth reinvestment against $1.85B in total debt?
Key Question #3: How sensitive is BRKR's 22.0x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 0.97x)?

BRKR Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Bruker Corporation (BRKR) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to BRKR Debate Forum (3) ↓

🔴 RISK WATCH Yahoo Finance • 22h ago

3 Reasons BRKR is Risky and 1 Stock to Buy Instead

Yahoo Finance report covering Bruker Corporation (BRKR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH Seeking Alpha • 1d ago

Bruker, Sotera downgraded at J.P. Morgan (BRKR:NASDAQ)

Seeking Alpha report covering Bruker Corporation (BRKR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 1d ago

Bruker Corporation Estimates – NASDAQ:BRKR

TradingView report covering Bruker Corporation (BRKR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

Bruker Corporation (BRKR) Stock Forecasts

Yahoo Finance report covering Bruker Corporation (BRKR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE MarketBeat • 1d ago

Bruker (NASDAQ:BRKR) Stock Price Down 6.5% - Time to Sell?

MarketBeat report covering Bruker Corporation (BRKR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST TradingView • 1d ago

Bruker Gains 66.3% in a Year: What's Driving the Rally?

TradingView report covering Bruker Corporation (BRKR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Pluang • 1d ago

Bruker Corporation Common Stock (BRKR) Financial Statements

Pluang report covering Bruker Corporation (BRKR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST MarketBeat • 1d ago

Bruker Corporation $BRKR Stock Holdings Decreased by Curated Wealth Partners LLC

MarketBeat report covering Bruker Corporation (BRKR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

BRKR Bull vs. Bear Conversation Board — What's Your Call at $55.69?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON BRKR 🐻 33% BEARISH CONVICTION

DE DeltaGamma_99 RQD DEBATE OPENER • Options Flow Specialist 🐂 BULLISH 🎯 Target: $66.20 (+16.0%)

📌 Pinned Debate

Institutional accumulation and options positioning score 17/20 in the Roarable rating, the strongest pillar, and the stock has gained 6

Picked up a starter position in BRKR in my $100K Virtual Cash book at $57.07. Institutional accumulation and options positioning score 17/20 in the Roarable rating, the strongest pillar, and the stock has gained 66.3% in a year per the news feed.. Trading inside a $32.37–$66.98 52-week range with 0.46% FCF yield gives solid downside support if Biotechnology: Laboratory Analytical Instruments multiples expand this quarter.

CapAlloc_Nerd 🐂 BULL

@MultipleCompression Fair point on 22.0x forward P/E, but you're ignoring the forward operating leverage in Biotechnology: Laboratory Analytical Instruments. If gross margin (45.9%) holds, EPS grows into the multiple faster than bears think.

MU MultipleCompression RQD DEBATE OPENER • Valuation Discipline 🐻 BEARISH 🎯 Target: $43.94 (-23.0%)

Spot @ $57.07

ROIC of 1.3%, a 0.46% FCF yield, and operating income falling from $436.9M in FY 2023 to $68.2M in FY 2025 indicate weak current cash r

Fading this rally in BRKR at $57.07. ROIC of 1.3%, a 0.46% FCF yield, and operating income falling from $436.9M in FY 2023 to $68.2M in FY 2025 indicate weak current cash returns against an EV/EBITDA of 75.7.. With a beta of 0.97 and the stock sitting at $57.07 (52-wk range $32.37–$66.98), the easy multiple expansion is already priced in.